Two tests and one reference [General Sta­tis­tics]

posted by Brus – Spain, 2020-08-31 09:58 (92 d 17:25 ago) – Posting: # 21895
Views: 2,638

Dear Helmut and all,

If one test and two references of different regions are tested in a bioequivalence study, is it necessary a α adjustment?

In my case, we want to demonstrate if the test product is bioequivalent to R1 (European product reference) or if test product is bioequivalent to R2 (Reference product in the United Kingdom).

If I have not misunderstood, in this case, alpha should be penalized, even if they are from different regions and to market in different regions because of the word "OR"?

Is there a way to not penalize alpha? If the "O" is changed to "AND"? Executing two different clinical trials (one for Europe and one for the UK)?

Best regards,

Complete thread:

 Admin contact
21,226 posts in 4,427 threads, 1,482 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 02:23 CET (Europe/Vienna)

A big data-analyst is an expert
in producing misleading conclusions from huge datasets.
It is much more efficient to use a statistician,
who can do the same with small ones.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz